Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LevoHeartShock: Early Levosimendan in Cardiogenic Shock
2024-513811-29-00Phase 3Authorised
- Sponsor
- CHRU Nancy
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cardiogenic shock comparing Levosimendan arm with Placebo arm (2 arms). Primary endpoint: Primary composite endpoint at day 30. Planned start Aug 2024; status: authorised.
02
Drugs
levosimendan
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on 2024-513811-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513811-29-00.